Ichiro Ogino1, Shigenobu Watanabe2, Noriaki Iwahashi3, Masami Kosuge3, Kentaro Sakamaki4, Chikara Kunisaki5, Kazuo Kimura3. 1. , 4-57 Urahune-cho, Minami-ku, Yokohama, Kanagawa-prefecture, Japan. ogino1ro@urahp.yokohama-cu.ac.jp. 2. , 4-57 Urahune-cho, Minami-ku, Yokohama, Kanagawa-prefecture, Japan. 3. Division of Cardiology, Yokohama City University Medical Center, Yokohama, Japan. 4. Department of Biostatistics, Yokohama City University Medical Center, Yokohama, Japan. 5. Department of Surgery, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.
Abstract
PURPOSE: To evaluate clinical and dosimetric factors retrospectively affecting the risk of symptomatic cardiac disease (SCD) in esophageal cancer patients treated with radiotherapy. PATIENTS AND METHODS: A total of 343 patients with newly diagnosed esophageal cancer were managed with concurrent chemoradiotherapy or radiotherapy alone. Of these, 58 patients were followed at our hospital for at least 4 years. Median clinical follow-up was 79 months. Cardiac toxicity was determined by Common Terminology Criteria for Adverse Events (CTCAE) v. 4.0. The maximum and mean doses to the heart and percentage of the volume were calculated from the dose-volume histograms. RESULTS: SCD manifested in 11 patients. The heart diseases included three pericardial effusions, one pericardial effusion with valvular disease and paroxysmal atrial tachycardia, three atrial fibrillations, one sinus tachycardia, one coronary artery disease, one chest pain with strongly suspected coronary artery disease, and one congestive heart failure. The actual incidence of SCD was 13.8 % at 5 years. Univariate and multivariate analyses of continuous variables revealed that the risk of developing an SCD depended on the volume of the heart receiving a dose greater than 45 Gy (V45), 50 Gy (V50), and 55 Gy (V55). No other clinical factors were found to influence the risk of SCD. For V45, V50, and V55, the lowest significant cutoff values were 15, 10, and 5 %, respectively. CONCLUSION: High-dose and large-volume irradiation of the heart increased the risk of SCD in long-term survivors. Using modern radiotherapy techniques, it is important to minimize the heart dose-volume parameters without reducing the tumor dose.
PURPOSE: To evaluate clinical and dosimetric factors retrospectively affecting the risk of symptomatic cardiac disease (SCD) in esophageal cancerpatients treated with radiotherapy. PATIENTS AND METHODS: A total of 343 patients with newly diagnosed esophageal cancer were managed with concurrent chemoradiotherapy or radiotherapy alone. Of these, 58 patients were followed at our hospital for at least 4 years. Median clinical follow-up was 79 months. Cardiac toxicity was determined by Common Terminology Criteria for Adverse Events (CTCAE) v. 4.0. The maximum and mean doses to the heart and percentage of the volume were calculated from the dose-volume histograms. RESULTS:SCD manifested in 11 patients. The heart diseases included three pericardial effusions, one pericardial effusion with valvular disease and paroxysmal atrial tachycardia, three atrial fibrillations, one sinus tachycardia, one coronary artery disease, one chest pain with strongly suspected coronary artery disease, and one congestive heart failure. The actual incidence of SCD was 13.8 % at 5 years. Univariate and multivariate analyses of continuous variables revealed that the risk of developing an SCD depended on the volume of the heart receiving a dose greater than 45 Gy (V45), 50 Gy (V50), and 55 Gy (V55). No other clinical factors were found to influence the risk of SCD. For V45, V50, and V55, the lowest significant cutoff values were 15, 10, and 5 %, respectively. CONCLUSION: High-dose and large-volume irradiation of the heart increased the risk of SCD in long-term survivors. Using modern radiotherapy techniques, it is important to minimize the heart dose-volume parameters without reducing the tumor dose.
Authors: Paul A Heidenreich; Steven L Hancock; Byron K Lee; Carol S Mariscal; Ingela Schnittger Journal: J Am Coll Cardiol Date: 2003-08-20 Impact factor: 24.094
Authors: Yi-Jen Chen; An Liu; Chunhui Han; Peter T Tsai; Timothy E Schultheiss; Richard D Pezner; Nilesh Vora; Dean Lim; Stephen Shibata; Kemp H Kernstine; Jeffrey Y C Wong Journal: Med Dosim Date: 2007 Impact factor: 1.482
Authors: Steven H Lin; Lu Wang; Bevan Myles; Peter F Thall; Wayne L Hofstetter; Stephen G Swisher; Jaffer A Ajani; James D Cox; Ritsuko Komaki; Zhongxing Liao Journal: Int J Radiat Oncol Biol Phys Date: 2012-08-03 Impact factor: 7.038
Authors: Nina-Sophie Hegemann; Rebecca Koepple; Franziska Walter; David Boeckle; Wolfgang P Fendler; Martin Kurt Angele; Stefan Boeck; Claus Belka; Falk Roeder Journal: Strahlenther Onkol Date: 2018-01-18 Impact factor: 3.621
Authors: Vijayalakshmi Sridharan; John W Seawright; Francis J Antonawich; Merrill Garnett; Maohua Cao; Preeti Singh; Marjan Boerma Journal: Radiat Res Date: 2017-02-23 Impact factor: 2.841
Authors: Milan Vošmik; Miroslav Hodek; David Buka; Petra Sýkorová; Jakub Grepl; Petr Paluska; Simona Paulíková; Igor Sirák Journal: Rep Pract Oncol Radiother Date: 2020-02-25
Authors: S Vivekanandan; D B Landau; N Counsell; D R Warren; A Khwanda; S D Rosen; E Parsons; Y Ngai; L Farrelly; L Hughes; M A Hawkins; J D Fenwick Journal: Int J Radiat Oncol Biol Phys Date: 2017-04-27 Impact factor: 7.038